Harpoon Therapeutics, Inc.: Nasdaq/NYSE listing notice — Harpoon Therapeutics receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days

Harpoon Therapeutics, Inc.

Nasdaq notified Harpoon that bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until May 29, 2023, to regain compliance.
To regain compliance, closing bid must be at least $1.00 for ten consecutive business days.
If not compliant by May 29, Harpoon may be eligible for an additional 180-day period if it meets other listing standards.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Harpoon Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

November 29, 2022, Harpoon Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. In

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-296516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.